Swiss firms invest $27 billion in U.S., but tariff threat looms

Switzerland is diligently fulfilling its investment promises to the United States, with Swiss companies pouring $27 billion into the U.S. economy between January and April. This significant investment is part of a larger commitment made in November, where Switzerland pledged $200 billion over five years to help avert punitive U.S. tariffs.

The list of investors reads like a who's who of the Swiss economy. Novartis is investing in a biomedical research center in San Diego and a cancer drug production facility in Texas. Roche is expanding its production in North Carolina, where medical technology company Ypsomed is also building a new factory. The logistics and classic industry sectors are also represented, with shipping company MSC opening a new North American headquarters in Miami and machine tool manufacturer Pfiffner Group and electronics firm Elma expanding their U.S. production capacities.

Rahul Sahgal, CEO of the Swiss-American Chamber of Commerce, stated that Switzerland is acting as a "model student" by meeting its obligations. However, the effectiveness of these investments in securing favorable trade relations remains uncertain. The U.S. has recently announced new tariffs on goods from countries perceived as not doing enough to combat forced labor. Switzerland, lacking an explicit import ban on goods produced by forced labor, finds itself in this category, facing a potential 12.5% tariff, while the EU faces 10%.

“

We are model students and fulfill our promises.